Leveraging Anti-Tumor Immunity with Radiopharmaceutical Therapy (RPT) and Potential Combinatorial Approaches with RPT and Immunotherapy

Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings. While there is long-standing interest in combining focal radiotherapy (e.g., external beam radiation therapy) with immunotherapy to generate systemic anti-tumor immune responses - there has been limited success in the translation of this approach to the clinic. In contrast, the systemic nature of RPT and distinct cellular and molecular mechanism of this modality offers an attractive partner for immune-based approaches. Promising preclinical and translational work has demonstrated that RPT can be immunostimulatory and synergistically combine with both EBRT and/or immunotherapy. Given several recent regulatory approvals, a growing number of clinical indications and increasing utilization in the clinic there is a need to characterize the immunogenicity of RPT in the clinic and to better understand how this modality can complement and/or be optimally combined with immune-based approaches to improve patient outcomes.

Topics:

  1. Application of PRO's to Clinical Trials
    Deborah W. Bruner, PhD, RN, FAAN
  2.  

This activity is available from December 1, 2025, through 11:59 p.m. Eastern time on November 30, 2027. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, dosimetrists and radiation biologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe RPT as a modality and review current clinical indications (FDA/regulatory approvals) and clinical trial landscape with an emphasis on combination approaches involving EBRT and/or Immunotherapy.
  • Discuss potential immunological mechanisms of RPT and explain potential synergy and combinatorial effects with immunotherapy based on preclinical and translational data.
  • Analyze and assess optimal approaches for the clinical integration of RPT + immunotherapy combination strategies to improve clinical outcomes. Determine potential avenues and multi-disciplinary pathways for radiation oncology to develop novel applications for RPT with a focus on immunotherapy/EBRT combinations.
     
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
12/01/2025
Course expires: 
11/30/2027
Cost:
$149.00
Rating: 
0
  • Erin F. Gillespie, MD, MPH, is employed by University of California, San Diego. Dr. Gillespie serves an uncompensated role as Co-founder of eContour.  
  •  

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until November 30, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.